Bibliography
- MURPHY PM, BAGGIOLINI M, CHARO IF et al.: International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors. Pharmacol. Rev. (2000) 52:145-176.
- MACKAY CR: Chemokines: immunology's high impact factors. Nat. Immunol. (2001) 2:95-101.
- CHARO IF, RANSOHOFF RM: The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. (2006) 354:610-21.
- PEASE JE, WILLIAMS TJ: The attraction of chemokines as a target for specific anti-inflammatory therapy. Br. J. Pharmacol. (2006) 147(Suppl. 1):S212-S221.
- MITSUYAMA E, KUNORI Y, KAMIMURA T, KAMINUMA O: Functional chemokine receptors in allergic diseases: is CCR8 a novel therapeutic target? Mini Rev. Med. Chem. (2006) 6:463-466.
- TIFFANY HL, LAUTENS LL, GAO JL et al.: Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309. J. Exp. Med. (1997) 186:165-70.
- NORMAN P: Chemokine antagonists in potential breakthrough therapeutics. In: Inflammatory And Metabolic Diseases; Promising, High Profile, Targeted Approaches. Cambridge Healthtech Associates, Woburn, MA, USA. (2007).
- JIN J, Y WANG, F WANG et al.: Oxazolidinones as novel human CCR8 antagonists. Biorg. Med. Chem. Letts. (2007) 17:1722-1725.
Patents
- MILLENNIUM PHARMACEUTICALS, INC.: WO2003037271 (2003).
- MILLENNIUM PHARMACEUTICALS, INC.: WO2004058736 (2004).
- MILLENNIUM PHARMACEUTICALS, INC.: WO2004058709 (2004).
- SMITHKLINE BEECHAM CORP.: WO2004032856 (2004).
- SMITHKLINE BEECHAM CORP.: WO2004073619 (2004).
- SMITHKLINE BEECHAM CORP.: WO2004074438 (2004).
- ASTRAZENECA AB: WO2005040167 (2005).
Websites
- http://www.astrazeneca.com/sites/7/imagebank/typearticleparam511679/astrazeneca-development-pipeline-feb-2007.pdf AstraZeneca website.